000276146 001__ 276146
000276146 005__ 20250209000706.0
000276146 0247_ $$2doi$$a10.1162/imag_a_00200
000276146 0247_ $$2altmetric$$aaltmetric:164748229
000276146 037__ $$aDZNE-2025-00218
000276146 082__ $$a610
000276146 1001_ $$0P:(DE-2719)2811369$$aHelbing, Cornelia$$b0$$eFirst author$$udzne
000276146 245__ $$aChemogenetic inhibition of dopaminergic neurons reduces stimulus-induced dopamine release, thereby altering the hemodynamic response function in the prefrontal cortex
000276146 260__ $$aCambridge, MA$$bMIT Press$$c2024
000276146 3367_ $$2DRIVER$$aarticle
000276146 3367_ $$2DataCite$$aOutput Types/Journal article
000276146 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738661595_16422
000276146 3367_ $$2BibTeX$$aARTICLE
000276146 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276146 3367_ $$00$$2EndNote$$aJournal Article
000276146 520__ $$aTo investigate the effect of endogenously released dopamine on the stimulus-induced blood oxygen level–dependent (BOLD) responses, we used rats expressing inhibitory designer receptors exclusively activated by designer drugs (DREADDs) in neurons of the ventral tegmental area (VTA) and electrically stimulated the fimbria/fornix. This stimulation activates multiple components of the mesolimbic dopamine system, as demonstrated by the BOLD signal changes during functional magnetic resonance imaging (fMRI) and dopamine release in the nucleus accumbens (NAcc) as detected by in vivo fast-scan cyclic voltammetry. Activation of inhibitory DREADDs by clozapine N-oxide (CNO) significantly reduced stimulus-induced dopamine release and the BOLD response in the NAcc. In contrast, the concurrently induced BOLD response in the medial prefrontal cortex (mPFC) was not significantly reduced after CNO administration, but the hemodynamic response was shifted to the left. Specifically, the Granger causality test showed that the temporal relationship between the BOLD signal changes in the hippocampus and the mPFC, changed. Under control conditions (i.e., in the absence of CNO), the BOLD signal changes in the mPFC and NAcc clearly preceded the BOLD signal changes in the right hippocampus, whereas in the presence of CNO this was only the case for the BOLD signal changes in the NAcc. In the control rats, that is, the rats that received a control virus and thus did not express DREADDs in the VTA, this CNO-mediated effect was not present. Our results indicate that activation of the endogenous dopaminergic system has region-specific effects on the stimulus-induced BOLD responses, so there is no generally applicable fMRI parameter that clearly indicates increased activity of the dopaminergic system.
000276146 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000276146 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000276146 7001_ $$aBrocka, Marta$$b1
000276146 7001_ $$0P:(DE-2719)2811871$$aArboit, Alberto$$b2$$udzne
000276146 7001_ $$aLippert, Michael T.$$b3
000276146 7001_ $$0P:(DE-2719)2810456$$aAngenstein, Frank$$b4$$eLast author$$udzne
000276146 773__ $$0PERI:(DE-600)3167925-0$$a10.1162/imag_a_00200$$gVol. 2, p. 1 - 16$$p1 - 16$$tImaging neuroscience$$v2$$x2837-6056$$y2024
000276146 8564_ $$uhttps://pub.dzne.de/record/276146/files/DZNE-2025-00218%20SUP.pdf
000276146 8564_ $$uhttps://pub.dzne.de/record/276146/files/DZNE-2025-00218.pdf$$yOpenAccess
000276146 8564_ $$uhttps://pub.dzne.de/record/276146/files/DZNE-2025-00218%20SUP.pdf?subformat=pdfa$$xpdfa
000276146 8564_ $$uhttps://pub.dzne.de/record/276146/files/DZNE-2025-00218.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276146 909CO $$ooai:pub.dzne.de:276146$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000276146 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811369$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000276146 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811871$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000276146 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810456$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000276146 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000276146 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276146 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-09-26T09:40:26Z
000276146 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-09-26T09:40:26Z
000276146 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276146 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-09-26T09:40:26Z
000276146 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000276146 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000276146 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000276146 9201_ $$0I:(DE-2719)1310004$$kAG Angenstein$$lFunctional Neuroimaging$$x0
000276146 980__ $$ajournal
000276146 980__ $$aVDB
000276146 980__ $$aUNRESTRICTED
000276146 980__ $$aI:(DE-2719)1310004
000276146 9801_ $$aFullTexts